Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 184

Related Citations for PubMed (Select 23125906)

1.

Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

Blüher M, Kurz I, Dannenmaier S, Dworak M.

World J Diabetes. 2012 Sep 15;3(9):161-9. doi: 10.4239/wjd.v3.i9.161.

2.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
3.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
4.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
5.

Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.

Rosenstock J, Fitchet M.

Int J Clin Pract Suppl. 2008 Mar;(159):15-23. doi: 10.1111/j.1742-1241.2007.01692.x. Review.

PMID:
18269437
6.

Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.

Göke R, Bader G, Dworak M.

Diabetes Ther. 2014 Jun;5(1):183-91. doi: 10.1007/s13300-014-0060-4. Epub 2014 Mar 19.

7.

Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.

Odawara M, Yoshiki M, Sano M, Hamada I, Lukashevich V, Kothny W.

Diabetes Ther. 2015 Mar;6(1):17-27. doi: 10.1007/s13300-015-0099-x. Epub 2015 Feb 18.

9.

Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

He YL.

Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Review.

PMID:
22339447
10.

Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.

Saab C, Al-Saber FA, Haddad J, Jallo MK, Steitieh H, Bader G, Ibrahim M.

Vasc Health Risk Manag. 2015 Feb 24;11:149-55. doi: 10.2147/VHRM.S73703. eCollection 2015.

11.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
12.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
13.

Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.

Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W.

World J Diabetes. 2013 Aug 15;4(4):151-6. doi: 10.4239/wjd.v4.i4.151.

14.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Filozof C, Gautier JF.

Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. Erratum in: Diabet Med. 2013 May;30(5):632.

PMID:
20536495
15.

Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study.

Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB, Uren E; GALATA Study Group.

Curr Med Res Opin. 2015 Apr;31(4):623-32. doi: 10.1185/03007995.2015.1019609. Epub 2015 Mar 16.

PMID:
25697921
16.

Translating science into clinical practice: focus on vildagliptin in combination with metformin.

Barnett AH.

Diabetes Obes Metab. 2009 May;11 Suppl 2:18-26. doi: 10.1111/j.1463-1326.2008.01030.x. Review.

PMID:
19385980
17.

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.

Odawara M, Hamada I, Suzuki M.

Diabetes Ther. 2014 Jun;5(1):169-81. doi: 10.1007/s13300-014-0059-x. Epub 2014 Mar 7.

18.

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S.

Horm Metab Res. 2008 Dec;40(12):892-5. doi: 10.1055/s-0028-1082334. Epub 2008 Aug 22.

PMID:
18726829
19.
20.

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.

Bolli G, Dotta F, Rochotte E, Cohen SE.

Diabetes Obes Metab. 2008 Jan;10(1):82-90. Epub 2007 Nov 22.

PMID:
18034842
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk